Case Report: Human Recombinant Growth Hormone Therapy in a DSH Cat Presented With Dwarfism

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F21%3A10436141" target="_blank" >RIV/00216208:11310/21:10436141 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60460709:41210/21:88278

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9KO7K_PmH-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9KO7K_PmH-</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fvets.2021.773355" target="_blank" >10.3389/fvets.2021.773355</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Case Report: Human Recombinant Growth Hormone Therapy in a DSH Cat Presented With Dwarfism

Popis výsledku v původním jazyce

A 6-month-old kitten, male, domestic shorthair cat was presented with dwarfism, ocular and nasal discharge, and Ascaris infestation. Congenital hyposomatotropism was diagnosed on the basis of serum level of insulin-like growth factor-1 (IGF-I). The cat was treated with human recombinant growth hormone for 9 weeks. After that, his liver enzymes became elevated, and the therapy was discontinued. His IGF-I levels were normal at the end of the therapy. Normal IGF-I was present 3 months after discontinuation of therapy with human recombinant growth hormone and even half a year after the discontinuation. All other comorbidities were addressed with the therapy. The cat is now the size of normal cats, living with the first author.

Název v anglickém jazyce

Case Report: Human Recombinant Growth Hormone Therapy in a DSH Cat Presented With Dwarfism

Popis výsledku anglicky

A 6-month-old kitten, male, domestic shorthair cat was presented with dwarfism, ocular and nasal discharge, and Ascaris infestation. Congenital hyposomatotropism was diagnosed on the basis of serum level of insulin-like growth factor-1 (IGF-I). The cat was treated with human recombinant growth hormone for 9 weeks. After that, his liver enzymes became elevated, and the therapy was discontinued. His IGF-I levels were normal at the end of the therapy. Normal IGF-I was present 3 months after discontinuation of therapy with human recombinant growth hormone and even half a year after the discontinuation. All other comorbidities were addressed with the therapy. The cat is now the size of normal cats, living with the first author.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Frontiers in Veterinary Science [online]

ISSN

2297-1769

e-ISSN

—

Svazek periodika

8

Číslo periodika v rámci svazku

November

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

8

Strana od-do

773355

Kód UT WoS článku

000733698300001

EID výsledku v databázi Scopus

2-s2.0-85120675123